No single measure was identified for use across the range of FND symptoms in adults .
Across r and omised controlled trials ( k=40 ) and observational treatment studies ( k=40 ) , outcome measures most often assessed core FND symptom change .
Other domains measured commonly were additional physical and psychological symptoms , life impact ( ie , quality of life , disability and general functioning ) and health economics/cost-utility ( eg , healthcare re source use and quality -adjusted life years ) .
CONCLUSIONS There are few well-vali date d FND-specific outcome measures .
OBJECTIVES We aim ed to identify existing outcome measures for functional neurological disorder ( FND ) , to inform the development of recommendations and to guide future research on FND outcomes .
Fatigue, not self-rated motor symptom severity, affects quality of life in functional motor disorders
While fatigue is found to be an impairing symptom in functional motor disorders ( FMD ) in clinical practice , scientific evidence is lacking . We investigated fatigue severity and subtypes in FMD compared to organic neurological disease . Furthermore , the role of fatigue within FMD and its impact on quality of life and self-rated health were investigated . Data from 181 patients participating in the self-help on the internet for functional motor disorders , r and omised Trial were included . Data from 217 neurological controls with neuromuscular disorders ( NMD ) originated from a historical cohort .  Fatigue was measured using the checklist individual strength ( CIS ) . Motor symptom severity , depression and anxiety were correlated to fatigue . For multivariable regression analyses , physical functioning and pain were additionally taken into account . Severe fatigue was , respectively , present in 78 and 53 % of FMD and NMD patients ( p < 0.001 ) . FMD patients scored higher than NMD patients on all fatigue subdomains ( p < 0.001 ) . In the FMD group , fatigue subdomains were correlated to depression , anxiety and partly to motor symptom severity . Quality of life was negatively associated with fatigue [ OR 0.93 ( 0.90–0.96 ) , p < 0.001 ] and depression [ OR 0.87 ( 0.81–0.93 ) , p < 0.001 ] , but not self-rated motor symptom severity . Self-rated health was negatively associated with fatigue [ OR 0.92 ( 0.88–0.96 ) , p < 0.001 ] and pain [ OR 0.98 ( 0.97–0.99 ) , p < 0.001 ] . Fatigue was found to be a prevalent problem in FMD , more so than in organic neurological disease . It significantly affected quality of life and self-rated health , while other factors such as motor symptom severity did not . Fatigue should be taken into account in clinical practice and treatment trials
No single measure was identified for use across the range of FND symptoms in adults .
Across r and omised controlled trials ( k=40 ) and observational treatment studies ( k=40 ) , outcome measures most often assessed core FND symptom change .
Other domains measured commonly were additional physical and psychological symptoms , life impact ( ie , quality of life , disability and general functioning ) and health economics/cost-utility ( eg , healthcare re source use and quality -adjusted life years ) .
CONCLUSIONS There are few well-vali date d FND-specific outcome measures .
OBJECTIVES We aim ed to identify existing outcome measures for functional neurological disorder ( FND ) , to inform the development of recommendations and to guide future research on FND outcomes .